Asset Management One Co. Ltd. Buys 6,590 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Asset Management One Co. Ltd. lifted its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 4.9% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 141,873 shares of the pharmaceutical company's stock after purchasing an additional 6,590 shares during the quarter. Asset Management One Co. Ltd. owned 0.06% of Vertex Pharmaceuticals worth $68,783,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Mascagni Wealth Management Inc. bought a new stake in shares of Vertex Pharmaceuticals in the 4th quarter valued at about $31,000. Truvestments Capital LLC lifted its position in shares of Vertex Pharmaceuticals by 30.3% in the fourth quarter. Truvestments Capital LLC now owns 99 shares of the pharmaceutical company's stock valued at $40,000 after buying an additional 23 shares during the last quarter. Mpwm Advisory Solutions LLC bought a new position in shares of Vertex Pharmaceuticals during the 4th quarter worth approximately $40,000. Midwest Capital Advisors LLC bought a new stake in Vertex Pharmaceuticals in the 4th quarter valued at $41,000. Finally, Minot DeBlois Advisors LLC bought a new position in Vertex Pharmaceuticals in the 4th quarter valued at about $44,000. Institutional investors own 90.96% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. Bank of America upped their target price on Vertex Pharmaceuticals from $555.00 to $567.00 and gave the company a "buy" rating in a research report on Monday, March 31st. Leerink Partnrs cut Vertex Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 6th. HC Wainwright reissued a "buy" rating and issued a $550.00 target price on shares of Vertex Pharmaceuticals in a research report on Monday. Leerink Partners reaffirmed a "market perform" rating and set a $503.00 price target (down from $550.00) on shares of Vertex Pharmaceuticals in a research report on Tuesday, May 6th. Finally, Needham & Company LLC restated a "hold" rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, May 6th. Fourteen analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $513.14.

Vertex Pharmaceuticals Trading Down 1.0%

Shares of VRTX stock traded down $4.57 during mid-day trading on Wednesday, reaching $445.70. 801,439 shares of the stock traded hands, compared to its average volume of 1,414,386. The company has a market cap of $114.45 billion, a price-to-earnings ratio of -113.70 and a beta of 0.41. The company has a quick ratio of 2.29, a current ratio of 2.65 and a debt-to-equity ratio of 0.01. The stock's fifty day simple moving average is $457.17 and its two-hundred day simple moving average is $459.32. Vertex Pharmaceuticals Incorporated has a 1-year low of $377.85 and a 1-year high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 EPS for the quarter, missing the consensus estimate of $4.29 by ($0.23). Vertex Pharmaceuticals had a negative return on equity of 3.36% and a negative net margin of 8.91%. The business had revenue of $2.77 billion for the quarter, compared to analyst estimates of $2.85 billion. During the same quarter in the prior year, the business earned $4.76 earnings per share. The firm's quarterly revenue was up 2.6% on a year-over-year basis. On average, research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.